Agilent Technologies' (A) Hold (C) Rating Reiterated at Weiss Ratings

Key Points

• Agilent Technologies' stock has been given a "hold (C)" rating by Weiss Ratings and has a consensus rating of "Moderate Buy" among analysts.
• Recent price target updates from various analysts have increased, with estimates now ranging from $142.00 to $165.00, reflecting positive sentiment around the stock.
• Agilent's shares recently increased by 2.3%, reaching $141.75, and the company reported a quarterly revenue of $1.74 billion, exceeding analyst expectations.

Agilent Technologies (NYSE:A - Get Free Report)'s stock had its "hold (c)" rating reiterated by stock analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts also recently weighed in on A. Robert W. Baird increased their price target on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Rothschild & Co Redburn started coverage on shares of Agilent Technologies in a research report on Wednesday. They set a "buy" rating and a $165.00 target price on the stock. Barclays lifted their target price on shares of Agilent Technologies from $125.00 to $150.00 and gave the company an "equal weight" rating in a research report on Thursday, October 2nd. Wells Fargo & Company lifted their target price on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Monday, September 15th. Finally, Evercore ISI lifted their target price on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an "in-line" rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $147.92.

Agilent Technologies Stock Up 2.3%

Shares of A stock traded up $3.19 on Wednesday, hitting $141.75. The company's stock had a trading volume of 477,771 shares, compared to its average volume of 1,936,409. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The firm's fifty day moving average price is $123.61 and its 200-day moving average price is $116.64. The stock has a market capitalization of $40.19 billion, a price-to-earnings ratio of 33.29, a P/E/G ratio of 4.62 and a beta of 1.26.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same period last year, the business posted $1.32 EPS. Agilent Technologies's revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Agilent Technologies by 13.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after purchasing an additional 4,362 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Agilent Technologies by 8.3% in the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after buying an additional 2,371 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Agilent Technologies by 29.5% in the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after buying an additional 3,040 shares during the period. D.A. Davidson & CO. boosted its holdings in shares of Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after buying an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. boosted its holdings in shares of Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after buying an additional 54,302 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.